DPP-4i in type 2 diabetes case study quiz
Work through a simulated case study of a type 2 diabetes patient who may benefit from dipeptidyl peptidase-4 inhibitors (DPP-4i) in this quiz.
AUSTRALIA'S #1 ONLINE CPD EDUCATION PLATFORM
Education
Gain a succinct overview of specific topics relating to every day practice with our wide range of education modules and advanced courses; quick and easy to complete anytime, anywhere. You will receive a certificate for completing any of these education activities. CPD points are also available. Our 40-point sessions provide the opportunity to develop indepth knowledge, skills, behaviour and attitudes in a range of therapeutic areas.
Live webinar - A new role for SGLT2 inhibitors in the management of HFrEF
Tuesday 19 July 2022, 7:00pm - 8:30pm AEST
This webinar will discuss important new guideline updates regarding diagnosis and treatment optimisation for people with heart failure with reduced ejection fraction (HFrEF), including the role that sodium-glucose transport 2 inhibitors (SGLT2i) play in first-line management.
Live webinar - Dementia risk reduction: Applying the evidence to optimise your patients’ brain health
Thursday 14 July 2022, 7:00pm - 8:30pm AEST
In this webinar, Dr Hilton Koppe, Dr Marita Long and Prof Kaarin Anstey explore the latest evidence to assess dementia risk, and apply the latest clinical guidelines to help prevent or delay the onset of dementia in your patients.
Long-acting injectable buprenorphine for the treatment of opioid dependence
Module 1 of 2: This learning module explores the nature of opioid dependence and the diagnostic criteria for opioid use disorder, then outlines the use of pharmacotherapies in medication assisted treatment of opioid dependence (MATOD) and the benefits of opioid agonist treatment including long-acting injectable buprenorphine (LAIB) products.
Practical use of long-acting injectable buprenorphine for the treatment of opioid dependence
Module 2 of 2: This two-part activity provides education on the various long-acting buprenorphine (LAIB) formulations available in Australia, followed by a practical exercise where the learner goes through the steps of assessing whether a patient is suitable for LAIB treatment, and discusses with them how treatment may help them achieve their goals.
Clinical audit: Heart health checks and lipid lowering therapies for primary prevention of CVD
In this clinical audit, you will conduct Heart Health Checks for your patients, providing comprehensive cardiovascular risk assessments and developing ongoing management plans involving pharmacological and lifestyle strategies to reduce cardiovascular risk.
GLP-1 receptor agonists in type 2 diabetes clinical audit
This clinical audit reviews GPs' use of the GLP-1 receptor agonist class of T2D medications in line with the latest Australian and international guidelines, supporting effective glycaemic management and improving patients' overall outcomes and quality of life.
GLP-1 receptor agonists in type 2 diabetes: Guidelines for initiating treatment with a GLP-1 RA
This one-hour module outlines the appropriate use of GLP-1 receptor agonists, as well as other oral and injectable agents, in the management of type 2 diabetes as per the latest Australian and international guidelines.
Pages
